Research Information System
Nouvelles Dermatologiques, vol.14, no.7, pp.428-431, 1995 (Scopus)
Acyclovir was administered orally in a double-blind, placebo controlled study to 75 Behcet patients who had predominantly mucocutaneous signs (treatment group n = 60, placebo group n = 15). Efficacy of acyclovir was studied by administering the drug in three different regimens: first group received acyclovir 200 mg 5 times daily for 5 days a month. Second group received acyclovir 200 mg 5 times daily for 5 days; this schedule was repeated two weeks later. Third group received acyclovir 200 mg twice daily. The treatment period was three months. When the results of the treatment groups were compared with those of the placebo group acyclovir was found to decrease the frequency and duration of attacks and number of lesions (p<0.01). The most effective treatment regimen was use of acyclovir 200 mg 5 times daily for 5 days a month (p = 0.06).